Drug Approval | January 03, 2024
Alembic Pharmaceuticals received 8 USFDA approvals in Q3FY24
The company has received five final approvals
The company has received five final approvals
Roche will pay a purchase price of USD 295 million and an additional payment of up to USD 55 million
Innovent will supply sintilimab for the collaborated clinical trial
Elpiscience will receive up to US $37 million, including the upfront payment and license option fees
The product is expected to be launched in December 2023
The transfer of the distribution rights will strengthen Sandoz's immunology and biosimilar portfolio
V116 is an investigational, 21-valent pneumococcal conjugate vaccine specifically designed to protect adults
Darunavir is a protease inhibitor antiviral medicine that prevents Human Immunodeficiency Virus (HIV-1) from multiplying in the body
The Regional Reference Laboratory in Chennai is equipped with cutting-edge diagnostic technologies
Conditional marketing authorization is based on clinically meaningful response rates, duration of response, and safety from the Phase 2 MagnetisMM-3 trial
Subscribe To Our Newsletter & Stay Updated
